RE:RE:RE:RE:RE:RE:13 years of survival<h4 class="TextLabel__text-label___3oCVw TextLabel__black___2FN-Z TextLabel__medium___t9PWg MarketStoryItem-headline-2cgfz" style="-webkit-text-size-adjust: auto; margin: 0px 0px 12px; padding: 0px; border: 0px; font-family: knowledge-medium, sans-serif; font-size: 20px; font-weight: inherit; font-stretch: inherit; line-height: 1.3; vertical-align: baseline; -webkit-font-smoothing: antialiased; color: rgb(49, 49, 50); flex-basis: 100%; align-self: flex-start; word-break: break-word;"> let me cut and paste seeing as your that forgetful. Its been at least 5 years since dealing with LXX and I might ask WTH has happened there anyway. LXX cut ties I imagine. See if you actually do DD the last 10 years you will find many many things that did not come to fruition not to mention. Its all a smoke screen<br /> DIDNT happen:<br /> Lexaria's Ambarii entered into LOI with Naturally Splendid Enterprises</h4> <p class="TextLabel__text-label___3oCVw TextLabel__gray___1V4fk TextLabel__serif___3lOpX MarketStoryItem-description-3kmoG" style="-webkit-text-size-adjust: auto; margin: 0px 0px 10px; padding: 0px; border: 0px; font-family: freight-book, serif; font-size: medium; font-stretch: inherit; line-height: 1.5; vertical-align: baseline; -webkit-font-smoothing: antialiased; color: rgb(113, 115, 117); flex-basis: 100%; align-self: flex-start; word-break: break-word;"> May 30 (Reuters) - Lexaria Bioscience Corp <LXX.CD>::Lexaria Bioscience - co's 50 percent owned JV unit Ambarii trade corporation has entered into a LOI with naturally Splendid Enterprises Ltd.Lexaria Bioscience - LOI for production, sale, distribution of Ambarii's proprietary sublingual full spectrum hemp cbd tablets in Japan and South Korea.Lexaria Bioscience Corp - in addition to revenue generated from product sales, Ambarii will also receive a royalty on all sales.Lexaria Bioscience-under terms, JV unit to manufacture, supply Ambarii CBD tablets to naturally splendid for exclusive distribution in Japan, South Korea.Lexaria Bioscience- JV unit expects Japan and South Korea markets to contribute to "meaningful revenue growth" in 2017 and 2018</p>